Advertisement
RCKT 외환 뉴스
Rocket Pharma Says FDA Grants Fast Track And Orphan Drug Designations For RP-A601 Gene Therapy
Biotechnology company Rocket Pharmaceuticals, Inc. (RCKT) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to RP-A601, the Company's gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM).
RTTNews
|
711 일 전
Rocket Pharma Says EMA Grants PRIME Designation For RP-A501 Gene Therapy For Danon Disease
Biotechnology company Rocket Pharmaceuticals, Inc. (RCKT) announced Wednesday that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501.
RTTNews
|
719 일 전
